An open label, phase II trial of afatinib with or without vinorelbine for the treatment of HER2-overexpressing Inflammatory Breast Cancer

Trial Profile

An open label, phase II trial of afatinib with or without vinorelbine for the treatment of HER2-overexpressing Inflammatory Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Afatinib (Primary) ; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 01 Dec 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 05 Nov 2014 Planned End Date changed from 1 Oct 2014 to 1 Nov 2014 as per ClinicalTrials.gov record.
    • 05 Nov 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Nov 2014 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top